Recent Study Might Help Design Drug For Lung Cancer – Researchers Reveals

NEWS DIGEST – Researchers in a new study, have discovered that the EP300 gene is responsible for the spread and inhibition of small cell lung cancer (SCLC) in mouse models.

The study which appeared in an advanced science journal on Monday reveals that the researchers were able to stop the spread of cancer in mouse models by manipulating the EP300 gene.

The study says an estimated 13 percent of diagnosed lung cancer is Small Cell Lung Cancer ( SCLC).

According to the National Organization for Rare Diseases, “Small Cell Lung Cancer ( SCLC) is an aggressive type of cancer characterized by rapid, uncontrolled growth of certain cells in the lungs”.

The researchers found out that the protein that the EP300 gene codes for can either promote or inhibit Small Cell Lung Cancer (SCLC).

The study Author, Dr. Kwon Sik Park, associate professor of microbiology and biology cancer at the University of Virginia School of Medicine in Charlottesville says that the preclinical model of the research shows that  EP300 is a multi-functional protein.

“Small Cell Lung Cancer (SCLC) developed if EP300 gene loss histone acetyltransferase protein domain function. However, the study also showed that the KIX domain of the mutant EP300, which remains intact, drives the disease”.

“Specifically, the protein-protein interactions mediated by the KIX domain of EP300 are critical for the survival of SCLC cells and vulnerable to inhibition. This was shown both in a mouse model as well as using human SCLC cell lines”.

“This validates the KIX domain of EP300 as a target for drug development for the treatment of SCLC, specifically a protein-protein interaction inhibitor of the KIX domain,” Dr. Park explained.

Dr. Charles Evans, research information manager at Cancer Research UK who was not involved in the study says the research highlights a key vulnerability that could be targeted for a potential new treatment, not only for small cell lung cancer but for all kinds of cancer.